Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Finalizes Medicare Rx Regs; Rebate Rules Await Further Guidance

Executive Summary

The Centers for Medicare & Medicaid Services will issue a guidance on how Part D plan sponsors should report rebates following the publication of the final implementing regulations

You may also be interested in...



Medicare Rx Risk-Sharing Deals Not Covered By Safe Harbors, Attorneys Say

Drug manufacturers and Medicare Part D drug plan sponsors may be misinterpreting the Medicare Modernization Act as they form risk-sharing arrangements, Sidley Austin Brown & Wood Partner William Sarraille told the Pharmaceutical Compliance Summit March 30 in Philadelphia

Medicare Rx Risk-Sharing Deals Not Covered By Safe Harbors, Attorneys Say

Drug manufacturers and Medicare Part D drug plan sponsors may be misinterpreting the Medicare Modernization Act as they form risk-sharing arrangements, Sidley Austin Brown & Wood Partner William Sarraille told the Pharmaceutical Compliance Summit March 30 in Philadelphia

New York EPIC Rx Plan Will Wrap Around Part D; Model For Other States?

New York plans to retain its state pharmaceutical assistance program once the Medicare Part D drug benefit goes into effect, EPIC Director Julie Naglieri said during the NACDS Medicare Prescription Drugs & Reform conference in Baltimore March 3

Related Content

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel